RxDoctor Payments Data

Nasir Sulemanjee

Advanced Heart Failure and Transplant Cardiology · Milwaukee, WINPI 1396940979

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (41.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Abbott at 52.1% of the total. Reporting peaked in 2023 at $4,604 and has fallen 79.8% since, to $931 in 2025.

$15,535in general payments, 2019–2025

Across 86 payments — averaging $180.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Ancora Heart, Inc.$4K
  • Medtronic$2K
  • Livanova USA, Inc.$574
  • Abiomed$427
  • Cvrx, Inc.$357
$459,759in research payments, 2019–2025

Across 174 payments — averaging $2642.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$420K
  • Transmedics, Inc.$15K
  • Novartis$10K
  • Pfizer$7K
  • Medtronic$4K
  • Amgen$4K

What the payments were for

  • Consulting fees$3,11520%
  • Travel & lodging$5,94138%
  • Food & beverage$6,47942%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott50$8,090
Ancora Heart, Inc.12$4,059
Medtronic13$2,029
Livanova USA, Inc.1$574
Abiomed5$427
Cvrx, Inc.5$357

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Wisconsinto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$62,057
Medicare patients
222
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis25$562,510
VyndaqelTafamidis Meglumine14$278,039
EntrestoSacubitril/Valsartan182$271,578
JardianceEmpagliflozin192$235,115
FarxigaDapagliflozin Propanediol58$62,712
EliquisApixaban65$61,002
Tacrolimus268$35,539
Mycophenolate Mofetil234$24,532
XareltoRivaroxaban12$17,578
Sirolimus43$13,084
Eplerenone63$4,861
Potassium Chloride100$4,814
Cyclosporine ModifiedCyclosporine, Modified26$3,973
Torsemide112$3,370
Valganciclovir Hcl17$2,838

Paid to pharmacies, not to this prescriber.

Other advanced heart failure and transplant cardiology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →